Document is current
Any future updates will be listed below
-
Authors
Leguia, Mariana
Vila-Sanjurjo, Antón
Juarez, Diana
Garcia-Glaessner, Alejandra
Gil, Ana I.
Alvarez, Mayita
Cornejo, Rubelio
Cherikh, Sami
Gelber, Casey E.
Goll, Johannes B.
Howard, Leigh M.
Jimenez-Truque, Natalia
Edwards, Kathryn M.
Creech, C. Buddy
Lanata, Claudio F.
-
Funding
Funding for this research was provided by:
NIH-NIAID (HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17, HSN2722001300023I, Task Order 17)
- License Information
-
More Information
Article History
Received: 11 November 2024
Accepted: 27 March 2025
First Online: 11 August 2025
Competing interests
: All authors (except CFL and KME) declare no financial or non-financial competing interests. CFL has funding from and is a consultant to HilleVax. He is also a member of the Data Safety Monitoring Board of Merck. KME has funding from NIH and CDC and is a consultant for Bionet, Dynavax and IBM. She is also a member of the Data Safety Monitoring Boards of Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, Roche, Novavax, and Brighton Collaboration.
